Immuneering (IMRX) to Release Earnings on Thursday

Immuneering (NASDAQ:IMRX) is projected to release its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect Immuneering to post earnings of ($0.31) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 8:00 AM ET.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Friday, March 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.13. On average, analysts expect Immuneering to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immuneering Price Performance

NASDAQ:IMRX opened at $5.65 on Thursday. The firm has a market capitalization of $365.27 million, a price-to-earnings ratio of -4.09 and a beta of 0.46. The business has a fifty day moving average price of $5.16 and a 200-day moving average price of $6.13. Immuneering has a one year low of $1.10 and a one year high of $10.08.

Wall Street Analyst Weigh In

Several research firms have recently commented on IMRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research note on Monday. Wall Street Zen raised shares of Immuneering from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Chardan Capital restated a “buy” rating and set a $20.00 target price on shares of Immuneering in a research note on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Insider Activity

In other Immuneering news, Director Thomas J. Schall acquired 21,645 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was purchased at an average price of $4.67 per share, with a total value of $101,082.15. Following the completion of the purchase, the director directly owned 74,530 shares in the company, valued at approximately $348,055.10. The trade was a 40.93% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Peter Feinberg bought 20,000 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average price of $4.35 per share, with a total value of $87,000.00. Following the transaction, the director directly owned 135,441 shares of the company’s stock, valued at $589,168.35. This represents a 17.32% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 51,819 shares of company stock worth $234,472 over the last 90 days. Company insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Immuneering

Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp lifted its holdings in shares of Immuneering by 1,289.7% in the fourth quarter. State Street Corp now owns 2,402,238 shares of the company’s stock worth $15,807,000 after buying an additional 2,229,374 shares in the last quarter. Vanguard Group Inc. increased its holdings in Immuneering by 128.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after acquiring an additional 1,358,322 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Immuneering in the 3rd quarter worth $6,602,000. Marshall Wace LLP boosted its holdings in shares of Immuneering by 162.4% during the 4th quarter. Marshall Wace LLP now owns 711,875 shares of the company’s stock valued at $4,684,000 after purchasing an additional 440,571 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Immuneering during the fourth quarter valued at about $2,098,000. Institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.